GoodRx Holdings (GDRX) Capital Expenditures (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Capital Expenditures data on file, last reported at $1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 94.77% year-over-year to $1.1 million; the trailing twelve-month figure through Mar 2026 stood at $49.9 million (up 121.12% YoY), and the FY2025 full-year result was $70.5 million, up 5585.4% from the prior year.
• Capital Expenditures retreated to $1.1 million in Q1 2026, from $14.6 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $41.8 million in Q3 2023 to a low of -$41.2 million in Q4 2023.
• A 5-year average of $4.6 million and a median of $1.1 million in 2026 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures tumbled 27578.0% in 2023 and surged 8905.56% in 2025, its largest moves.
• Tracing GDRX's Capital Expenditures over 5 years: stood at $150000.0 in 2022, then plunged by 27578.0% to -$41.2 million in 2023, then jumped by 100.39% to $162000.0 in 2024, then surged by 8905.56% to $14.6 million in 2025, then tumbled by 92.21% to $1.1 million in 2026.
• Business Quant data shows GDRX's Capital Expenditures at $1.1 million in Q1 2026, $14.6 million in Q4 2025, and $16.3 million in Q3 2025.